The combination of VEGFR2 inhibitors and PD-1 inhibitors has been shown to induce vascular normalization in HCC, reducing vascular leakage, improving tumor perfusion, and thereby promoting immune cell infiltration into tumor tissues [151]. Here, PDCD1 is linked to hepatocellular carcinoma.